Bruno Pougault on the Limitations of DOACs in High-Risk Conditions
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn:
”DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease”
Read the full article here.
Article: When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review
Authors: Antoine Bejjani, Candrika D. Khairani, Ali Assi, Gregory Piazza, Parham Sadeghipour, Azita H. Talasaz, John Fanikos, Jean M. Connors, Deborah M. Siegal, Geoffrey D. Barnes, Karlyn A. Martin, Dominick J. Angiolillo, Dawn Kleindorfer, Manuel Monreal, David Jimenez, Saskia Middeldorp, Mitchell S. V. Elkind, Christian T. Ruff, Samuel Z. Goldhaber, Harlan M. Krumholz, Roxana Mehran, Mary Cushman, John W. Eikelboom, Gregory Y. H. Lip, Jeffrey I. Weitz, Renato D. Lopes, Behnood Bikdeli
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 16, 2025, 16:56Kathryn Mikkelsen on The Beat: Vasculearn Network’s Newsletter for Clot Survivors
-
Dec 16, 2025, 16:50Raul Santos on Sex-Specific Biology and Plasma Fructose Levels in Cardiovascular Risk
-
Dec 16, 2025, 16:34Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
-
Dec 16, 2025, 16:22Leonardo Furtado Freitas Presents a Rare Hemorrhagic Hemangioblastoma Case
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms